{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:17:29Z","timestamp":1790648249582,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001516","name":"National Heart Foundation of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["JGC 10_027"],"award-info":[{"award-number":["JGC 10_027"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Plasma concentrations of B-type natriuretic peptide (BNP) or its amino terminal congener (NT-proBNP) are used for HF diagnosis and risk stratification. Because BNP concentrations are inexplicably lowered in obese patients, we investigated the relationship between proBNP glycosylation, plasma NT-proBNP, and body mass index (BMI) in HF patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Three assays were developed to distinguish between total proBNP (glycosylated plus nonglycosylated proBNP), proBNP not glycosylated at threonine 71 (NG-T71), and proBNP not glycosylated in the central region (NG-C). Intraassay and interassay CVs were &amp;lt;15%; limits of detection were &amp;lt;21 ng\/L; and samples diluted in parallel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULT<\/jats:title>\n                  <jats:p>Applying these assays and an NT-proBNP assay to plasma samples from 106 healthy volunteers and 238 HF patients determined that concentrations [median (interquartile range)] of proBNP, NG-T71, and NT-proBNP were greater in HF patients compared with controls [300 (44\u2013664), 114 (18\u2013254), and 179 (880\u20133459) ng\/L vs 36 (18\u2013229), 36 (18\u2013175), and 40 (17\u201368) ng\/L, respectively; all P &amp;lt; 0.012]. NG-C was undetectable in most samples. ProBNP concentrations in HF patients with BMI more or less than 30 kg\/m2 were not different (P = 0.85), whereas HF patients with BMI &amp;gt;30 kg\/m2 had lower NT-proBNP and NG-T71 concentrations (P &amp;lt; 0.003) and higher proBNP\/NT-proBNP and proBNP\/NG-T71 ratios (P = 0.001 and P = 0.02, respectively) than those with BMI &amp;lt;30 kg\/m2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Increased BMI is associated with decreased concentrations of proBNP not glycosylated at T71. Decreased proBNP substrate amenable to processing could partially explain the lower NT-proBNP and BNP concentrations observed in obese individuals, including those presenting with HF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2019.302547","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T18:45:14Z","timestamp":1557945914000},"page":"1115-1124","source":"Crossref","is-referenced-by-count":34,"title":["ProBNP That Is Not Glycosylated at Threonine 71 Is Decreased with Obesity in Patients with Heart Failure"],"prefix":"10.1093","volume":"65","author":[{"given":"Lynley K","family":"Lewis","sequence":"first","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara D","family":"Raudsepp","sequence":"first","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C R","family":"Prickett","sequence":"first","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G","family":"Yandle","sequence":"first","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N","family":"Doughty","sequence":"first","affiliation":[{"name":"Cardiovascular Research Group, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Frampton","sequence":"first","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Pemberton","sequence":"first","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Mark","family":"Richards","sequence":"first","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand"},{"name":"Cardiac Department, Cardiovascular Research Institute, National University Heart Centre, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,1]]},"reference":[{"key":"2020022605535354200_B1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2265.1997.2361058.x","article-title":"Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment","volume":"47","author":"Hunt","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020022605535354200_B2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cca.2011.03.006","article-title":"Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing","volume":"412","author":"Semenov","year":"2011","journal-title":"Clin Chim Acta"},{"key":"2020022605535354200_B3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0140-6736(94)92690-5","article-title":"Plasma brain natriuretic peptide in assessment of acute dyspnoea","volume":"343","author":"Davis","year":"1994","journal-title":"Lancet"},{"key":"2020022605535354200_B4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0196-9781(97)00245-3","article-title":"The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32","volume":"18","author":"Hunt","year":"1997","journal-title":"Peptides"},{"key":"2020022605535354200_B5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jacc.2009.02.095","article-title":"N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial","volume":"55","author":"Lainchbury","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2020022605535354200_B6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2006.10.063","article-title":"Evidence for functional heterogeneity of circulating B-type natriuretic peptide","volume":"49","author":"Liang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2020022605535354200_B7","unstructured":"A table of BNP and NT-pro-BNP diagnostic assays and antibodies used in them is available on the International Federation of Clinical Chemistry and Laboratory Medicine website. http:\/\/www.ifcc.org\/media\/477439\/bnp-nt-probnp-and-mr-proanp-assays-analytical-characteristics-designated-by-manufacturer-v08232018.pdf (Accessed April 2019)."},{"key":"2020022605535354200_B8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1373\/clinchem.2005.061770","article-title":"Assay for measurement of intact B-type natriuretic peptide prohormone in blood","volume":"52","author":"Giuliani","year":"2006","journal-title":"Clin Chem"},{"key":"2020022605535354200_B9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2011.01.005","article-title":"Pro-B-type natriuretic peptide(1\u2013108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction","volume":"57","author":"Macheret","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2020022605535354200_B10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1373\/clinchem.2016.269712","article-title":"Development of a BNP1\u201332 immunoassay that does not cross-react with proBNP","volume":"63","author":"Lewis","year":"2017","journal-title":"Clin Chem"},{"key":"2020022605535354200_B11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/CIRCHEARTFAILURE.109.903153","article-title":"Simultaneous assessment of unprocessed proBNP1\u2013108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure","volume":"3","author":"Dries","year":"2010","journal-title":"Circ Heart Failure"},{"key":"2020022605535354200_B12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2020022605535354200_B13","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2020022605535354200_B14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archinte.167.4.400","article-title":"Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea","volume":"167","author":"Bayes-Genis","year":"2007","journal-title":"Arch Intern Med"},{"key":"2020022605535354200_B15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ahj.2005.10.011","article-title":"How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study","volume":"151","author":"Daniels","year":"2006","journal-title":"Am Heart J"},{"key":"2020022605535354200_B16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1373\/clinchem.2006.076141","article-title":"The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure","volume":"53","author":"Seferian","year":"2007","journal-title":"Clin Chem"},{"key":"2020022605535354200_B17","first-page":"832","article-title":"Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure","volume":"76","author":"Yandle","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020022605535354200_B18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/hrt.2009.178392","article-title":"Diversity of molecular forms of plasma brain natriuretic peptide in heart failure\u2014different proBNP-108 to BNP-32 ratios in atrial and ventricular overload","volume":"96","author":"Nishikimi","year":"2010","journal-title":"Heart"},{"key":"2020022605535354200_B19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1373\/clinchem.2007.097998","article-title":"Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage","volume":"54","author":"Luckenbill","year":"2008","journal-title":"Clin Chem"},{"key":"2020022605535354200_B20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1373\/clinchem.2016.263749","article-title":"Specificity of B-type natriuretic peptide assays: cross-reactivity with different BNP, NT-proBNP, and proBNP peptides","volume":"63","author":"Saenger","year":"2017","journal-title":"Clin Chem"},{"key":"2020022605535354200_B21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.abb.2006.03.028","article-title":"The precursor to B-type natriuretic peptide is an O-linked glycoprotein","volume":"451","author":"Schellenberger","year":"2006","journal-title":"Arch Biochem Biophys"},{"key":"2020022605535354200_B22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1373\/clinchem.2007.100040","article-title":"Immunodetection of glycosylated NT-proBNP circulating in human blood","volume":"54","author":"Seferian","year":"2008","journal-title":"Clin Chem"},{"key":"2020022605535354200_B23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1373\/clinchem.2016.265397","article-title":"Unraveling the molecular complexity of O-glycosylated endogenous (N-terminal) pro-B-type natriuretic peptide forms in blood plasma of patients with severe heart failure","volume":"63","author":"Halfinger","year":"2017","journal-title":"Clin Chem"},{"key":"2020022605535354200_B24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1373\/clinchem.2009.140558","article-title":"Effect of sialylated O-glycans in pro-brain natriuretic peptide stability","volume":"56","author":"Jiang","year":"2010","journal-title":"Clin Chem"},{"key":"2020022605535354200_B25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1373\/clinchem.2010.157438","article-title":"Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes","volume":"57","author":"Tonne","year":"2011","journal-title":"Clin Chem"},{"key":"2020022605535354200_B26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1373\/clinchem.2010.143883","article-title":"Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases","volume":"56","author":"Semenov","year":"2010","journal-title":"Clin Chem"},{"key":"2020022605535354200_B27","doi-asserted-by":"crossref","first-page":"e003601","DOI":"10.1161\/JAHA.116.003601","article-title":"Mir30-galnt1\/2 axis-mediated glycosylation contributes to the increased secretion of inactive human prohormone for brain natriuretic peptide (proBNP) from failing hearts","volume":"6","author":"Nakagawa","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2020022605535354200_B28","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/eurheartj\/ehu314","article-title":"Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure","volume":"35","author":"Vodovar","year":"2014","journal-title":"Eur Heart J"},{"key":"2020022605535354200_B29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/heartjnl-2011-300102","article-title":"The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure","volume":"98","author":"Nishikimi","year":"2012","journal-title":"Heart"},{"key":"2020022605535354200_B30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1373\/clinchem.2015.239673","article-title":"Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study","volume":"61","author":"Rosjo","year":"2015","journal-title":"Clin Chem"},{"key":"2020022605535354200_B31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cardfail.2013.01.007","article-title":"The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design","volume":"19","author":"Santhanakrishnan","year":"2013","journal-title":"J Card Fail"},{"key":"2020022605535354200_B32","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"2020022605535354200_B33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.peptides.2013.10.004","article-title":"Value of proBNP1\u2013108 testing for the risk stratification of patients with systolic heart failure","volume":"50","author":"Gruson","year":"2013","journal-title":"Peptides"},{"key":"2020022605535354200_B34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijcard.2017.12.047","article-title":"Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: a novel compensatory mechanism for acute heart failure","volume":"258","author":"Takahama","year":"2018","journal-title":"Int J Cardiol"},{"key":"2020022605535354200_B35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2020022605535354200_B36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ejhf.1226","article-title":"The paradox of low B-type natriuretic peptide levels in obesity revisited: does gender matter?","volume":"20","author":"Clerico","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2020022605535354200_B37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1507\/endocrj.EJ12-0239","article-title":"Cardiac production of B-type natriuretic peptide is inversely related to the plasma level of free fatty acids in obese individuals\u2014possible involvement of the insulin resistance","volume":"60","author":"Mizuno","year":"2013","journal-title":"Endocr J"},{"key":"2020022605535354200_B38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12933-017-0601-z","article-title":"NTproBNP in insulin-resistance mediated conditions: overweight\/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato study","volume":"16","author":"Baldassarre","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2020022605535354200_B39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1758-5996-6-96","article-title":"O-GlcNAC modification is associated with insulin sensitivity in the whole blood of healthy young adult males","volume":"6","author":"Myslicki","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"2020022605535354200_B40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1042\/BST20160164","article-title":"O-GlcNACylation and cardiovascular disease","volume":"45","author":"Wright","year":"2017","journal-title":"Biochem Soc Trans"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/65\/9\/1115\/32639168\/clinchem1115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/65\/9\/1115\/32639168\/clinchem1115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T05:59:48Z","timestamp":1582696788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/65\/9\/1115\/5608507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,1]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2019.302547","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,9,1]]}}}